Criteria for Verification and Replanning Based on the Adaptive Radiotherapy Protocol "Best for Adaptive Radiotherapy" in Head and Neck Cancer.
adaptive radiotherapy
head and neck cancer
helical tomotherapy
image-guided radiation therapy
radiotherapy planning
replanning
Journal
Life (Basel, Switzerland)
ISSN: 2075-1729
Titre abrégé: Life (Basel)
Pays: Switzerland
ID NLM: 101580444
Informations de publication
Date de publication:
12 May 2022
12 May 2022
Historique:
received:
13
04
2022
revised:
06
05
2022
accepted:
09
05
2022
entrez:
28
5
2022
pubmed:
29
5
2022
medline:
29
5
2022
Statut:
epublish
Résumé
No clear criteria have yet been established to guide decision-making for patient selection and the optimal timing of adaptive radiotherapy (ART) based on image-guided radiotherapy (IGRT). We have developed a novel protocol—the Best for Adaptive Radiotherapy (B-ART) protocol—to guide patient selection for ART. The aim of the present study is to describe this protocol, to evaluate its validity in patients with head and neck (HN) cancer, and to identify the anatomical and clinical predictors of the need for replanning. We retrospectively evaluated 82 patients with HN cancer who underwent helical tomotherapy (HT) and subsequently required replanning due to soft tissue changes upon daily MVCT. Under the proposed criteria, patients with anatomical changes >3 mm on three to four consecutive scans are candidates for ART. We compared the volumes on the initial CT scan (iCT) and the replanning CT (rCT) scan for the clinical target volumes (CTV1, referring to primary tumor or tumor bed and CTV2, metastatic lymph nodes) and for the parotid glands (PG) and body contour (B-body). The patients were stratified by primary tumor localization, clinical stage, and treatment scheme. The main reasons for replanning were: (1) a planning target volume (PTV) outside the body contour (n = 70; 85.4%), (2) PG shrinkage (n = 69; 84.1%), (3) B-body deviations (n = 69; 84.1%), and (4) setup deviations (n = 40; 48.8%). The replanning decision was made, on average, during the fourth week of treatment (n = 47; 57.3%). The mean reductions in the size of the right and left PG volumes were 6.31 cc (20.9%) and 5.98 cc (20.5%), respectively (p < 0.001). The reduction in PG volume was ≥30% in 30 patients (36.6%). The volume reduction in all of the anatomical structures was statistically significant. Four variables—advanced stage disease (T3−T4), chemoradiation, increased weight loss, and oropharyngeal localization—were significantly associated with the need for ART. The B-ART protocol provides clear criteria to eliminate random errors, and to allow for an early response to relevant changes in target volumes.
Identifiants
pubmed: 35629389
pii: life12050722
doi: 10.3390/life12050722
pmc: PMC9144703
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Radiother Oncol. 2020 Dec;153:88-96
pubmed: 32579998
Int J Radiat Oncol Biol Phys. 2010 Jun 1;77(2):617-21
pubmed: 20138444
Strahlenther Onkol. 2012 Mar;188(3):243-7
pubmed: 22294198
Clin Oncol (R Coll Radiol). 2012 Apr;24(3):208-15
pubmed: 22196796
Int J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):355-62
pubmed: 16256277
Int J Radiat Oncol Biol Phys. 2012 Jul 1;83(3):986-93
pubmed: 22138459
Asian Pac J Cancer Prev. 2016;17(3):985-92
pubmed: 27039824
Int J Radiat Oncol Biol Phys. 2013 Nov 15;87(4):676-82
pubmed: 24035328
J Med Phys. 2014 Jul;39(3):164-8
pubmed: 25190995
Med Dosim. 2016 Summer;41(2):154-8
pubmed: 26993081
Int J Radiat Oncol Biol Phys. 2008 Mar 1;70(3):875-82
pubmed: 18262099
J Cancer Res Ther. 2019 Jul-Sep;15(3):533-538
pubmed: 31169216
Radiat Oncol. 2013 Nov 27;8:277
pubmed: 24279414
Radiother Oncol. 2015 Oct;117(1):83-90
pubmed: 26277855
Pract Radiat Oncol. 2019 Jul - Aug;9(4):e422-e431
pubmed: 30836190
Radiat Oncol. 2019 Nov 1;14(1):189
pubmed: 31675962
Int J Radiat Oncol Biol Phys. 2016 Nov 1;96(3):653-60
pubmed: 27681762
Med Dosim. 2014 Spring;39(1):34-7
pubmed: 24140235
Biomed Res Int. 2015;2015:670327
pubmed: 25793202
Radiother Oncol. 2016 Jul;120(1):41-7
pubmed: 27372223
Int J Radiat Oncol Biol Phys. 2009 Nov 1;75(3):924-32
pubmed: 19801104
Int J Radiat Oncol Biol Phys. 2009 Nov 1;75(3):725-33
pubmed: 19362781
Int J Radiat Oncol Biol Phys. 2012 Mar 1;82(3):e375-82
pubmed: 22197229
Radiother Oncol. 2011 Jan;98(1):23-7
pubmed: 21040992
Technol Cancer Res Treat. 2014 Jun;13(3):233-42
pubmed: 24066951
J Med Imaging Radiat Oncol. 2010 Oct;54(5):497-504
pubmed: 20958950
Asia Pac J Clin Oncol. 2016 Dec;12(4):460-467
pubmed: 27435432
Biomed Res Int. 2015;2015:476383
pubmed: 26793717
Head Neck. 2014 Apr;36(4):499-504
pubmed: 23780633
J Radiat Res. 2014 Mar 1;55(2):293-304
pubmed: 23988444
Int J Radiat Oncol Biol Phys. 2013 Jan 1;85(1):e47-54
pubmed: 23122981
Int J Radiat Oncol Biol Phys. 2008 Mar 15;70(4):1256-62
pubmed: 18234431
Radiother Oncol. 2014 Aug;112(2):155-64
pubmed: 25443859
BJR Open. 2020 Dec 11;2(1):20200051
pubmed: 33367201
Radiat Oncol. 2016 Jun 08;11:79
pubmed: 27278960
Br J Radiol. 2016 Jun;89(1062):20160085
pubmed: 26986461
BMC Cancer. 2013 Nov 16;13:548
pubmed: 24237861
Head Neck. 2014 Nov;36(11):1541-6
pubmed: 23996502
Front Oncol. 2020 Nov 12;10:579917
pubmed: 33282734
Cancer Radiother. 2022 May;26(3):502-516
pubmed: 34772603
J Appl Clin Med Phys. 2017 Sep;18(5):64-69
pubmed: 28703475